SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Medical - Drugs >

Apricus Biosciences, Inc. (APRI)

APRI RSS Feed
Add APRI Price Alert      Hide Sticky   Hide Intro
Moderator: PuuliTuku
Search This Board: 
Last Post: 8/12/2017 10:00:24 AM - Followers: 189 - Board type: Free - Posts Today: 0

Apricus Biosciences, Inc. (APRI) 

 

 

http://www.apricusbio.com/

 

 

 

 

Company Address:

11975 El Camino Real, Suite 300
San Diego, CA 92130
T (858) 222-8041

 CIK:   0001017491

Apricus Website:    http://www.apricusbio.com/index.html

 

 
 

NexACT® - Multi-Route Drug Delivery Technology

NexACT® Multi-Route drug delivery technology facilitates compounds crossing the lipid bilayer and yet biodegrades in vivo to natural amino acids and natural fatty acids.

This technology is useful for:
  • Penetrating, proprietary, topical & transdermal formulations.
    Improving oral bioavailability of poorly soluble, poorly permeating compounds (BCS class 2-4)
    Delivering siRNA therapeutics into the cells; in vivo validated
    Development of more effective, penetrating cosmeceutic formulations
    Preservative

The safety and permeation properties of this proprietary drug delivery technology was demonstrated in the Vitaros® product which was approved for the treatment of erectile dysfunction in November 2010 by Health Canada, and approved by the European Union in June 2013.  Vitaros has been launched in all European Union countries by partner pharmaceutical companies.  Additional agreements for marketing Vitaros have been established.  For more information see the company's most recent 10K SEC filing.

In September 2015 the company anounced an agreement with Allergan to reacquire marketing rights for Vitaros in the U.S.  The company expects to resubmit a filing for FDA approval of Vitaros in the second half of 2016.  For more information see the company's most recent 10K SEC filing.


The company expects to initiate a Phase IIb clinical trial for RayVa to treat Reynaud's Syndrome in the second half of 2016.

In October 2014, the company acquired U.S. development and licensing rights to Fispemifene, a Selective Estrogen-Receptor Modulator (SERM) for treatment of secondary hypogonadism.  In March 2016 the company discontinued development Fispemifene after disappointing Phase IIb results.
.

 Filings:  http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0001017491&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Share Structure:
Outstanding Shares
 61,78M

Authorized Shares
75,000,000
  

Investor Relations:
ir@apricusbio.com
Tel: +1-858 222-8041

Matthew Beck
The Trout Group
:(646)378 2933

 

 

 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

 

Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

 


                                                                           
Image result for vitaros                                                  

Image result for vitaros

APRI
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
APRI News: Current Report Filing (8-k) 08/02/2017 04:09:02 PM
APRI News: Quarterly Report (10-q) 08/02/2017 04:07:42 PM
APRI News: Apricus Biosciences Provides Corporate Update and Second Quarter 2017 Financial Results 08/02/2017 04:01:10 PM
APRI News: Apricus Biosciences Provides Corporate Update and Second Quarter 2017 Financial Results 08/02/2017 04:01:00 PM
APRI News: Apricus Biosciences Announces Corporate Update and Second Quarter 2017 Financial Results Conference Call 07/26/2017 07:00:14 AM
PostSubject
#27356   APRI for sale. Are you nuts. Pascoe would casinokid11211 08/12/17 10:00:24 AM
#27355   The tax loss for Apri is 300 million Aprilov 08/09/17 11:22:26 AM
#27354   It looks like the board has guesstimates Ranging mecosmo2 08/08/17 12:27:53 PM
#27353   didn't know about the lawsuit, thanks, doesn't seem eicoman 08/08/17 09:58:11 AM
#27352   The question is, Why would a huge growing OldtimeramI 08/08/17 01:59:57 AM
#27351   The question is, Why would a huge growing eicoman 08/07/17 03:22:18 PM
#27350   I like it, but should that be through? Clariske 08/07/17 11:16:30 AM
#27349   I see, thanks for correction. PuuliTuku 08/07/17 09:28:49 AM
#27348   It looks like we did wake up the mecosmo2 08/07/17 09:24:24 AM
#27347   One more thing: "As of March 2015, the PuuliTuku 08/07/17 06:07:50 AM
#27346   Yes I am serious. PuuliTuku 08/07/17 05:52:11 AM
#27345   Are you guys serious? OldtimeramI 08/07/17 04:28:06 AM
#27344   I think you are in a reasonable range mecosmo2 08/06/17 04:05:53 PM
#27343   But to answer in aprilov's absense, I'll throw PuuliTuku 08/06/17 11:44:09 AM
#27342   Dont forget DDAIP HCL outlicensing to combine with PuuliTuku 08/06/17 11:38:04 AM
#27341   A little help for the number crunchers . mecosmo2 08/06/17 10:20:28 AM
#27340   Hey Casino, you do the math you seem mecosmo2 08/06/17 09:36:41 AM
#27339   Never thought Pascoe would ever submit the NDA. casinokid11211 08/05/17 10:04:27 AM
#27336   You heard it here first: NDA filing PuuliTuku 08/02/17 04:42:47 PM
#27335   Beats on earnings And on schedule for FDA mecosmo2 08/02/17 04:17:24 PM
#27334   You heard it here first !!! Casino is Aprilov 08/02/17 04:15:50 PM
#27332   earnings out tomorrow gapper $$$ myop kingsransome 08/01/17 11:12:11 AM
#27331   breakout $1.70+++ myop hold tite $$$$ kingsransome 08/01/17 10:58:50 AM
#27330   Approval in Mexico and Canada AND the BIG mecosmo2 07/31/17 09:28:08 AM
#27329   SAN DIEGO, July 26, 2017 (GLOBE NEWSWIRE) -- mecosmo2 07/27/17 08:34:13 AM
#27328   APRI buy 1.19 stocktrademan 07/26/17 10:52:43 AM
#27327   absolutely correct OT. Other countries have approved and eicoman 07/20/17 02:26:27 PM
#27326   Apri holders get one benefit from Mexico if OldtimeramI 07/20/17 10:17:34 AM
#27325   many Pharmacies close to the border will carry eicoman 07/20/17 10:01:32 AM
#27324   Apri holders get one benefit from Mexico if PuuliTuku 07/20/17 03:04:31 AM
#27323   yes OT, it's been a terrible ride, the eicoman 07/19/17 02:36:18 PM
#27322   How many years did we wait for this OldtimeramI 07/19/17 02:28:05 PM
#27321   http://www.benavides.com.mx/Branch eicoman 07/19/17 10:10:37 AM
#27320   https://www.fahorro.com/storelocator/index/indexcms/ Sucursal Seleccionada: eicoman 07/19/17 10:09:05 AM
#27319   Vitaros in Mexico will be available during the eicoman 07/19/17 09:56:48 AM
#27318   Vitaros U.S. NDA Re-Submission on Track for Third mecosmo2 07/12/17 08:34:59 PM
#27317   Oldtimer I 100% agree with you ., Aprilov 07/12/17 12:42:06 PM
#27316   I quote Matt Beck " I was informed Aprilov 07/12/17 12:40:44 PM
#27315   Not saying that the Human Factors Study is OldtimeramI 07/12/17 12:35:32 PM
#27314   +1 (646) 378-2933 matt beck feel free to Aprilov 07/12/17 11:10:43 AM
#27313   Why didn't Matt Beck tell you the test casinokid11211 07/11/17 07:14:23 PM
#27312   Almost 3 million volume today, any guesses wtf PuuliTuku 07/11/17 06:42:47 PM
#27311   As per matt beck study was 100% completed Aprilov 07/11/17 10:26:01 AM
#27310   news leaking,,may xploddddeeeee $17+ myop$$$ kingsransome 07/11/17 09:44:27 AM
#27309   So there was no stiffening of penises and PuuliTuku 07/05/17 07:54:47 PM
#27308   According to Matt Beck, Human Factors Study test casinokid11211 07/01/17 08:01:17 AM
#27307   If you lift the skirt high enough you shurtha2000 06/23/17 11:39:04 AM
#27306   Very active shurtha2000 06/23/17 11:25:02 AM
#27305   On the other hand, this news is over PuuliTuku 06/21/17 01:51:46 PM
#27304   Possible effect on APRI? PuuliTuku 06/21/17 01:50:15 PM
PostSubject